Details of Disease

General Information of Disease (ID: DISKQ2K7)

• Disease Name: Hypercalcaemia
• Synonyms: hypercalcemia
• Disease Class: 5B91: Mineral excesses
• Definition: Abnormally high concentration of calcium in the peripheral blood.
• Disease Hierarchy:
  DISNEQBZ: Disorder of calcium metabolism
  DISKQ2K7: Hypercalcaemia
• ICD Code:
  ICD-11: ICD-11: 5B91.0
  ICD-9: ICD-9: 275.42
  Expand ICD-9: 275.42
• Disease Identifiers:
  MONDO ID: MONDO_0001566
  MESH ID: D006934
  UMLS CUI: C0020437
  MedGen ID: 5686
  HPO ID: HP:0003072
  SNOMED CT ID: 66931009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 8 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cholecalciferol	DMGU74E	Approved	Small molecular drug	[1]
Clodronate	DM9Y6X7	Approved	Small molecular drug	[2]
Gallium nitrate	DMF9O6B	Approved	Small molecular drug	[3]
Ibandronate	DM0QZBN	Approved	Small molecular drug	[4]
Incadronate	DM3DSVJ	Approved	Small molecular drug	[5]
Pamidronate	DMB4AVP	Approved	Small molecular drug	[6]
Plicamycin	DM7C8YV	Approved	Small molecular drug	[5]
Zoledronate	DMIXC7G	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Edetic acid	DM10D85	Investigative	Small molecular drug	[7]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 19 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
PPY	TTIB95A	Limited	Biomarker	[8]
CALCA	TTVSFJW	moderate	Genetic Variation	[9]
CALCR	TTLWS2O	moderate	Therapeutic	[10]
PTH1R	TTFPD47	moderate	Genetic Variation	[11]
ASRGL1	TT4WT91	Strong	Biomarker	[12]
GAST	TT4LRVO	Strong	Biomarker	[13]
GNA11	TTSRXJW	Strong	Genetic Variation	[14]
HLA-DRB1	TTUXSTW	Strong	Genetic Variation	[15]
IDS	TTNY2AP	Strong	Biomarker	[16]
LGMN	TTPTWV5	Strong	Altered Expression	[17]
PTH2R	TTEPJL5	Strong	Altered Expression	[18]
RET	TT4DXQT	Strong	Genetic Variation	[19]
S100A12	TTQ4ESF	Strong	Altered Expression	[20]
SLC12A1	TTS087L	Strong	Genetic Variation	[21]
TNFRSF11B	TT2CJ75	Strong	Genetic Variation	[22]
TNFSF11	TT9E8HR	Strong	Biomarker	[23]
TRPC3	TTNVC34	Strong	Altered Expression	[24]
TRPV6	TTBK14N	Strong	Biomarker	[25]
ALPL	TTMR5UV	Definitive	Biomarker	[26]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC34A1	DT42EWA	Limited	Genetic Variation	[27]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP27B1	DE3FYEM	moderate	Altered Expression	[28]
NAT10	DEZV4AP	Strong	Biomarker	[12]

This Disease Is Related to 27 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AP2S1	OTEV2XGW	Limited	Genetic Variation	[29]
ELN	OTFSO7PG	Limited	Genetic Variation	[30]
HLF	OTTRK9XN	Limited	Genetic Variation	[31]
SPINK1	OTSUVAL2	Limited	Genetic Variation	[32]
MEN1	OTN6U6V0	moderate	Biomarker	[33]
AFG3L2	OTRPMAUX	Strong	CausalMutation	[34]
ALPP	OTZU4G9W	Strong	Biomarker	[12]
AQP2	OTQLBKK6	Strong	Biomarker	[35]
ATRNL1	OTY5JUX2	Strong	Biomarker	[12]
BGLAP	OTK1YLWQ	Strong	Biomarker	[36]
CCL27	OTUZYC61	Strong	Biomarker	[12]
CCNDBP1	OTBWG1M0	Strong	Biomarker	[37]
CLDN14	OTS7GKOI	Strong	Biomarker	[38]
DERL2	OTI3TUUZ	Strong	Biomarker	[39]
FKBP6	OTDFQV81	Strong	Genetic Variation	[40]
HLA-DRB3	OT5PM9N7	Strong	Biomarker	[41]
KL	OTD4VWU6	Strong	Altered Expression	[42]
MAU2	OTALDF8Q	Strong	Biomarker	[43]
MIP	OTEBLU3E	Strong	Biomarker	[44]
OSCP1	OTZ4IFGJ	Strong	Biomarker	[45]
PDLIM3	OTVXQC81	Strong	Biomarker	[12]
PTRH1	OTOAOS93	Strong	Biomarker	[46]
SCNN1G	OTSJYQVQ	Strong	Biomarker	[47]
SEPTIN4	OTD16B30	Strong	Biomarker	[48]
TRPV5	OTWF4L0U	Strong	Biomarker	[49]
BAZ1B	OTD5KR2J	Definitive	Biomarker	[50]
GCM2	OTSKNPTI	Definitive	Genetic Variation	[51]

References

• [1] Cholecalciferol FDA Label
• [2] Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
• [3] Drug information of Gallium nitrate, 2008. eduDrugs.
• [4] Ibandronate FDA Label
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7259).
• [7] Experimental hypercalcaemia and whole blood clotting. J Clin Pathol. 1973 Aug;26(8):616-9.
• [8] Pancreatic endocrine tumors: recent advances.Ann Oncol. 1999;10 Suppl 4:170-6.
• [9] Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms.Endocrine. 2019 May;64(2):384-392. doi: 10.1007/s12020-018-1773-3. Epub 2018 Oct 2.
• [10] Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice.J Bone Miner Res. 2008 Aug;23(8):1182-93. doi: 10.1359/jbmr.080310.
• [11] Nonparathyroid Hypercalcemia.Front Horm Res. 2019;51:77-90. doi: 10.1159/000491040. Epub 2018 Nov 19.
• [12] The chloride/phosphate ratio combined with alkaline phosphatase as a valuable predictive marker for primary hyperparathyroidism in Chinese individuals.Sci Rep. 2017 Jul 7;7(1):4868. doi: 10.1038/s41598-017-05183-6.
• [13] Multiple endocrine neoplasia type 1 (MEN 1) is associated with an increased prevalence of diabetes mellitus and impaired fasting glucose.Clin Endocrinol (Oxf). 2006 Aug;65(2):163-8. doi: 10.1111/j.1365-2265.2006.02563.x.
• [14] Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss-of-Function G(11) Mutation.J Bone Miner Res. 2018 Jan;33(1):32-41. doi: 10.1002/jbmr.3241. Epub 2017 Sep 22.
• [15] HLA-alleles associated with increased risk for extra-pulmonary involvement in sarcoidosis.Tissue Antigens. 2014 Apr;83(4):267-72. doi: 10.1111/tan.12326.
• [16] Case report: acute clinical presentation and neonatal management of primary hyperparathyroidism due to a novel CaSR mutation.BMC Pediatr. 2018 Oct 30;18(1):340. doi: 10.1186/s12887-018-1319-0.
• [17] Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption.J Biol Chem. 1999 Sep 24;274(39):27747-53. doi: 10.1074/jbc.274.39.27747.
• [18] Mental Effects of Excess Parathyroid Hormone in Hemodialysis Patients: A Possible Role for Parathyroid 2 Hormone Receptor?.Ther Apher Dial. 2020 Jun;24(3):285-289. doi: 10.1111/1744-9987.13429. Epub 2019 Sep 11.
• [19] Primary hyperparathyroidism as the first clinical manifestation of multiple endocrine neoplasia type 2A in a 5-year-old child.Thyroid. 2011 May;21(5):547-50. doi: 10.1089/thy.2010.0336. Epub 2011 Mar 30.
• [20] Characterization of the calcitonin/CGRP gene in Williams syndrome.Am J Med Genet. 1991 Apr 1;39(1):28-33. doi: 10.1002/ajmg.1320390108.
• [21] A novel SLC12A1 gene mutation associated with hyperparathyroidism, hypercalcemia, nephrogenic diabetes insipidus, and nephrocalcinosis in four patients.Bone. 2017 Apr;97:121-125. doi: 10.1016/j.bone.2017.01.011. Epub 2017 Jan 14.
• [22] Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK.Bone. 2014 Nov;68:153-61. doi: 10.1016/j.bone.2014.07.019. Epub 2014 Jul 23.
• [23] Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review.Bone. 2019 Mar;120:482-486. doi: 10.1016/j.bone.2018.12.012. Epub 2018 Dec 17.
• [24] Williams-Beuren syndrome hypercalcemia: is TRPC3 a novel mediator in calcium homeostasis?.Pediatrics. 2012 Jun;129(6):e1626-30. doi: 10.1542/peds.2011-2507. Epub 2012 May 7.
• [25] Activation of the calcium sensing receptor attenuates TRPV6-dependent intestinal calcium absorption.JCI Insight. 2019 Apr 23;5(11):e128013. doi: 10.1172/jci.insight.128013.
• [26] Hypercalcaemia in a Patient with 2p13.2-p16.1 Duplication.Horm Res Paediatr. 2016;85(3):213-8. doi: 10.1159/000442747. Epub 2015 Dec 17.
• [27] Rare Cause of Infantile Hypercalcemia: A Novel Mutation in the SLC34A1 Gene.Horm Res Paediatr. 2019;91(4):278-284. doi: 10.1159/000492899. Epub 2018 Sep 18.
• [28] Malakoplakia as a cause of severe hypercalcemia through ectopic 25-hydroxyvitamin D3 1-alpha-hydroxylase expression: A case report.Medicine (Baltimore). 2018 Oct;97(40):e12090. doi: 10.1097/MD.0000000000012090.
• [29] Cinacalcet Treatment in an Adolescent With Concurrent 22q11.2 Deletion Syndrome and Familial Hypocalciuric Hypercalcemia Type 3 Caused by AP2S1 Mutation.J Clin Endocrinol Metab. 2015 Jul;100(7):2515-8. doi: 10.1210/jc.2015-1518. Epub 2015 May 20.
• [30] Delineation of the common critical region in Williams syndrome and clinical correlation of growth, heart defects, ethnicity, and parental origin.Am J Med Genet. 1998 Jun 16;78(1):82-9. doi: 10.1002/(sici)1096-8628(19980616)78:1<82::aid-ajmg17>3.0.co;2-k.
• [31] Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19.Leukemia. 2007 Feb;21(2):288-96. doi: 10.1038/sj.leu.2404496. Epub 2006 Dec 21.
• [32] Cinacalcet sustainedly prevents pancreatitis in a child with a compound heterozygous SPINK1/AP2S1 mutation.Pancreatology. 2019 Sep;19(6):801-804. doi: 10.1016/j.pan.2019.07.045. Epub 2019 Jul 30.
• [33] Parental Multiple Endocrine Neoplasia Type 1 (MEN 1) Is Associated with Increased Offspring Childhood Mortality.J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz231. doi: 10.1210/clinem/dgz231.
• [34] Missense mutations in the AFG3L2 proteolytic domain account for ?1.5% of European autosomal dominant cerebellar ataxias. Hum Mutat. 2010 Oct;31(10):1117-24. doi: 10.1002/humu.21342.
• [35] Autophagy and renal epithelial transport: eat to survive.Kidney Int. 2017 May;91(5):1003-1005. doi: 10.1016/j.kint.2017.01.033.
• [36] Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form?.Am J Surg. 2020 Jan;219(1):150-153. doi: 10.1016/j.amjsurg.2019.10.032. Epub 2019 Oct 22.
• [37] A tumor-secreted protein associated with human hypercalcemia of malignancy. Biology and molecular biology.Ann N Y Acad Sci. 1988;548:137-45. doi: 10.1111/j.1749-6632.1988.tb18800.x.
• [38] Claudins and mineral metabolism.Curr Opin Nephrol Hypertens. 2016 Jul;25(4):308-13. doi: 10.1097/MNH.0000000000000239.
• [39] MIL-125-NH(2)@TiO(2) Core-Shell Particles Produced by a Post-Solvothermal Route for High-Performance Photocatalytic H(2) Production.ACS Appl Mater Interfaces. 2018 May 16;10(19):16418-16423. doi: 10.1021/acsami.8b01462. Epub 2018 May 2.
• [40] A novel human gene FKBP6 is deleted in Williams syndrome.Genomics. 1998 Sep 1;52(2):130-7. doi: 10.1006/geno.1998.5412.
• [41] HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites.Am J Hum Genet. 2003 Oct;73(4):720-35. doi: 10.1086/378097. Epub 2003 Aug 20.
• [42] Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23.Front Endocrinol (Lausanne). 2018 Jun 21;9:333. doi: 10.3389/fendo.2018.00333. eCollection 2018.
• [43] Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation.Biochem Biophys Res Commun. 2000 Mar 16;269(2):532-6. doi: 10.1006/bbrc.2000.2314.
• [44] Over-expression of CCL3 MIP-1alpha in a blastoid mantle cell lymphoma with hypercalcemia.Eur J Haematol. 2010 May;84(5):448-52. doi: 10.1111/j.1600-0609.2009.01405.x. Epub 2010 Dec 24.
• [45] The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.Clin Cancer Res. 2000 Mar;6(3):901-8.
• [46] Advances in the treatment of hypoparathyroidism with PTH 1-34.Bone. 2019 Mar;120:535-541. doi: 10.1016/j.bone.2018.09.018. Epub 2018 Sep 21.
• [47] Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.J Bone Miner Res. 1998 Sep;13(9):1378-83. doi: 10.1359/jbmr.1998.13.9.1378.
• [48] MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase.J Steroid Biochem Mol Biol. 2013 Nov;138:427-34. doi: 10.1016/j.jsbmb.2013.09.002. Epub 2013 Sep 14.
• [49] Structure-based characterization of novel TRPV5 inhibitors.Elife. 2019 Oct 25;8:e49572. doi: 10.7554/eLife.49572.
• [50] Importance of dietary calcium and vitamin D in the treatment of hypercalcaemia in Williams-Beuren syndrome.J Pediatr Endocrinol Metab. 2014 Jul;27(7-8):757-61. doi: 10.1515/jpem-2013-0229.
• [51] New Concepts About Familial Isolated Hyperparathyroidism.J Clin Endocrinol Metab. 2019 Sep 1;104(9):4058-4066. doi: 10.1210/jc.2018-02789.